Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
See Latest ArticlesDocetaxel and irinotecan in recurrent or metastatic head and neck cancer
Cancer, 07/31/09
Argiris A et al. - In a trial to evaluate combination docetaxel and irinotecan in the treatment of pts with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), it was suggested that docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected pts with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.
Methods- Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters.
- Pts received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on days 1 and 8, every 21 days, until disease progression.
- UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF were assessed in baseline tumor tissue.
- 52 pts were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of pts had distant metastasis, and 60% were paclitaxel-exposed.
- In Group A, 3 (15%) pts achieved a partial response; in Group B, 1 (3%) pt achieved a partial response.
- Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 mos in Group A and 1.9 and 5.0 mos in Group B, respectively.
- Common serious toxicities were diarrhea, fatigue, and anorexia.
- Pts with high serum VEGF had a median PFS of 2.8 mos vs 1.7 mos for pts with low VEGF.
Related Articles
Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy
Bulletin du Cancer, 10/19/09
Relevance Score: 88%
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
Cancer Chemotherapy and Pharmacology, 10/21/09
Relevance Score: 87%
Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk
International Journal of Epidemiology, 10/08/09
Relevance Score: 84%
Planned neck dissection following primary chemoradiation for advanced-stage head and neck cancer
Otolaryngology Head and Neck Surgery, 10/13/09
Relevance Score: 83%
Extracts from The Cochrane Library: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
Otolaryngology Head and Neck Surgery, 10/12/09
Relevance Score: 83%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis
Allergy and Asthma Proceedings, 12/17/09
Single dose of preoperative analgesia with gabapentin (600 mg) is safe and effective in monitored anesthesia care for nasal surgery
European Archives of Oto-Rhino-Laryngology, 12/16/09
The shelf life of antimicrobial ear drops
The Laryngoscope, 12/15/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Secondary surgery in paediatric facial paralysis reanimation
Journal of Plastic, Reconstructive & Aesthetic Surgery, 12/18/09
Dizziness and vertigo in an older population: the Blue Mountains prospective cross-sectional study
Clinical Otolaryngology, 12/18/09
When will I see you again? Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients
Clinical Otolaryngology, 12/18/09
Article Search
Sponsor